5.49
3.17%
-0.18
Pre-market:
5.35
-0.14
-2.55%
Evotec SE ADR stock is currently priced at $5.49, with a 24-hour trading volume of 55,778.
It has seen a -3.17% decreased in the last 24 hours and a -21.68% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.65 pivot point. If it approaches the $5.54 support level, significant changes may occur.
Previous Close:
$5.67
Open:
$5.59
24h Volume:
55,778
Market Cap:
$1.95B
Revenue:
$862.29M
Net Income/Loss:
$-103.88M
P/E Ratio:
-16.08
EPS:
-0.3415
Net Cash Flow:
$22.94M
1W Performance:
+4.17%
1M Performance:
-21.68%
6M Performance:
-44.21%
1Y Performance:
-50.45%
Evotec SE ADR Stock (EVO) Company Profile
Evotec SE ADR Stock (EVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Dec-09-22 | Initiated | H.C. Wainwright | Buy |
Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
Mar-02-22 | Resumed | Cowen | Outperform |
Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec SE ADR Stock (EVO) Latest News
Evotec gains R&D license from Centogene for Gaucher disease - Investing.com India
Investing.com India
EQS-HV: Evotec SE: Bekanntmachung der Einberufung zur Hauptversammlung am 10.06.2024 in Hamburg mit dem ... - sharewise
sharewise
Closing Bell Recap: Evotec SE ADR (EVO) Ends at 5.23, Reflecting a -31.63 Downturn – DWinneX - The Dwinnex
The Dwinnex
Earnings call: Evotec SE meets 2023 guidance, appoints new CEO - Investing.com UK
Investing.com UK
T. Rowe Price Raises Stake in Evotec SE - TipRanks.com - TipRanks
TipRanks
Evotec, Defense Metals, Paypal – hier ist Bewegung, wo lohnt sich ein Einstieg? - INV3ST
INV3ST
Evotec SE ADR Stock (EVO) Financials Data
Evotec SE ADR (EVO) Revenue 2024
EVO reported a revenue (TTM) of $862.29 million for the quarter ending December 31, 2023, a +13.86% rise year-over-year.
Evotec SE ADR (EVO) Net Income 2024
EVO net income (TTM) was -$103.88 million for the quarter ending December 31, 2023, a +46.88% increase year-over-year.
Evotec SE ADR (EVO) Cash Flow 2024
EVO recorded a free cash flow (TTM) of $22.94 million for the quarter ending December 31, 2022, a +488.59% increase year-over-year.
Evotec SE ADR (EVO) Earnings per Share 2024
EVO earnings per share (TTM) was -$0.2885 for the quarter ending December 31, 2023, a +48.99% growth year-over-year.
About Evotec SE ADR
Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health. It has collaboration agreements with Bayer AG; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Celgene; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Cap:
|
Volume (24h):